Researchers from the Royal Melbourne Hospital and Peter MacCallum Cancer Centre, along with other affiliated organizations, have published details on the synthesis and in vivo characterization of a novel series of 177Lu-labeled peptides with strong binding affinity to the cholecystokinin CCK2 receptor, an important molecular target which is highly expressed in a range of cancers.